Exploring Novel Protein Degraders & Maximizing Therapeutic Window in Degrader-Antibody-Conjugates
- Leveraging targeted protein degradation to expand therapeutic reach
- Differentiated MOA compared to existing ADC payloads
- Designing linkers to maximize therapeutic window